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Introduction
Pertussis or whooping cough is an immune-preventable
respiratory disease that is still endemic worldwide among
infants. This age group is most at risk of morbidity, hos-
pitalization and mortality. Estimates from WHO suggest
that in 2008, about 16 million cases of pertussis occurred
world-wide, 95% of which were in developing countries,
and that about 195 000 children died from the disease
(World Health Organization 2010). The best way to pre-
vent this highly contagious disease is to get vaccinated.
Two types of pertussis vaccines are available: whole-cell
(wP) vaccines based on killed aetiological pathogen
(Bordetella pertussis) and acellular (aP) vaccines based on
highly purified, selected bacterial components. Although
for paediatric population, wP or aP vaccines could be
used, for adolescent and adults, only aP vaccine with
lower dose of immunogens is recommended to reduce
the reactogenicity associated with the other vaccine
formulations (World Health Organization 2010).
The optimal pertussis immunization schedule and the
appropriate time for booster dose in a country are nor-
mally assessed based on its current epidemiological situa-
tion. Because of that, epidemiological surveillance of
pertussis is encouraged worldwide. Moreover, the
reported shift in the antigenic characteristics of Bord. per-
tussis circulating strains (Mooi et al. 1998; Hozbor et al.
2009) makes such surveillance crucial to evaluate the
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Abstract
Aim: To characterize Bordetella pertussis vaccine strains in comparison with
current circulating bacteria.
Methods and Results: Genomic and proteomic analyses of Bp137 were
performed in comparison with other vaccine strains used in Latin America
(Bp509 and Bp10536) and with the clinical Argentinean isolate Bp106. Tohama
I strain was used as reference strain. Pulse-field gel electrophoresis (PFGE) and
pertussis toxin promoter (ptxP) sequence analysis revealed that Bp137 groups
with Bp509 in PFGE group III and contains ptxP2 sequence. Tohama I (group
II) and Bp10536 (group I) contain ptxP1 sequence, while Bp106 belongs to a
different PFGE cluster and contains ptxP3. Surface protein profiles diverged in
at least 24 peptide subunits among the studied strains. From these 24 differen-
tial proteins, Bp10536 shared the expression of ten proteins with Tohama I and
Bp509, but only three with Bp137. In contrast, seven proteins were detected
exclusively in Bp137 and Bp106.
Conclusions: Bp137 showed more features in common with the clinical isolate
Bp106 than the other vaccine strains here included.
Significance and Impact of the Study: The results presented show that the old
strains included in vaccines are not all equal among them. These findings
together with the data of circulating bacteria should be taken into account to
select the best vaccine to be included in a national immunization programme.
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potential impact of bacterial shift on the overall immu-
nity of a population. To control the increasing number of
pertussis cases, many countries that do not produce vac-
cines must import the vaccine doses required to handle
the demands of its population. In countries where wP
vaccines are still being used, the selection of the vaccine
to be imported is a challenge in itself because not all vac-
cines are formulated with the same strain or the same
combination of strains. Latin American countries are
using wP vaccines that contain among others the
Bord. pertussis strains Bp10536, Bp509 and Bp137. In our
previous work, we have characterized the first two vaccine
strains (Bp10536 and Bp509) and have observed not only
differences between them but also a representative isolate
of the currently circulating bacterial population. Bp137
strain has been included in a Brazilian vaccine successfully
used in their national vaccination programme for more
than 17 years (Pereira et al. 2005). However, the proper-
ties of this strain are scarcely studied. In this work, we
present the results obtained from proteomic and genomic
studies on this strain and their comparison with those
from other vaccine strains. Results from the current
clinical isolate Bp106 were also included.
Materials and methods
Bacterial strains and growth conditions
The strains of Bord. pertussis used in this study were
Tohama I (Kasuga et al. 1954a,b,c) obtained from the
collection of the Pasteur Institute, France, Bp509 (van
Hemert 1969) obtained from the Netherlands Vaccine
Institute, and Bp10536 (Stainer and Scholte 1970) and
Bp137 (Pereira et al. 2005) obtained from the National
Administration of Laboratories and Institutes of Health.
The last three strains are widely used in wP vaccines in
Latin America (Table 1). The Argentinean clinical isolate,
Bp106, which was collected in 2001 from an infant patient
residing in Buenos Aires, was also included (Bottero et al.
2007). The strains and isolates were cultured on Bordet–
Gengou agar (BGA, Difco) supplemented with 1%
glycerol, Bacto-peptone (Difco) 10 g l)1 and 10% (v ⁄ v)
defibrinated sheep blood and incubated at 36°C for
3 days. Then, the bacteria were replated in the same med-
ium for 24 h. Bacterial suspensions prepared from these
plates were used for genomic analysis [PCR, sequencing
and pulse-field gel electrophoresis (PFGE)].
For proteomic experiments, subcultures were grown in
Stainer–Scholte liquid medium (Stainer and Scholte 1970)
for 20 h at 36°C until the optical density at 650 nm
reached 1Æ0.
PCR, sequencing and PFGE
PCR, sequencing and PFGE were performed as previously
described (Mooi et al. 2000, 2009; Hardwick et al. 2002b;
van Loo et al. 2002; Fiett et al. 2003; Advani et al. 2004;
Schouls et al. 2004; Borisova et al. 2007; Bottero et al.
2007). The sequences of the primers used to amplify and
sequence the promoter region of pertussis toxin (ptxP),
subunit A of pertussis toxin (ptxA), pertactin (prn), and
type 2 (fim2) and type 3 (fim3) fimbriae are given in
Table 2.
The obtained XbaI PFGE profiles were analysed using
BioNumerics (Applied Maths, Sint-Martens-Latem,
Belgium) software version 3.5. The unweighted pair group
method with arithmetic mean (UPGMA) algorithm was
used as the clustering method, with a 1% band tolerance
and 1% optimization settings with the Dice’s coefficient.
The band pattern of each strain was verified by visual
comparison. PFGE profiles were classified into groups
based on a criterion of similarity higher than 82%.
Table 1 Vaccine strains used in this study
Vaccine
strain
Origin of
the strain
Year of
isolation
wP vaccine–manufacturing
countries in Latin America
Before 1996 At present
Tohama I Japan 1954 Chile None
Bp509 the
Netherlands
1950 Cuba
Mexico
Venezuela
Cuba
Mexico
Venezuela
Bp10536 USA Before
1940
Argentina
Colombia
None
Bp137 USA No data
available
Ecuador
Uruguay
Brazil
Brazil
Ecuador
Table 2 Primers used in this study
Gene Primer sequence References
ptxP F: 5¢-AATCGTCCTGCTCAACCGCC-3¢ Schouls et al.
(2004), Mooi
et al. (2009)
R: 5¢-GGTATACGGTGGCGGGAGGA-3¢
ptxA F: 5¢-CCCCTGCCATGGTGTGATC-3¢ Fiett et al.
(2003)R: 5¢-TCAATTACCGGAGTTGGGCG-3¢
prn F: 5¢-CAATGTCACGGTCCAA-3¢ Mooi et al.
(2000)R: 5¢-GCAAGGTGATCGACAGGG-3¢
fim2 F: 5¢-GCGCCGGGCCCTGCATGCAC-3¢ Van Loo and
Mooi (2002),
Borisova et al.
(2007)
R: 5¢-GGGGGGTTGGCGATTTCCAGTTCTC-3¢
fim3 F: 5¢-GACCTGATATTCTGATGCCG-3¢ Borisova et al.
(2007)R: 5¢-AAGGCTTGCCGGTTTTTTTTGG-3¢
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Serotyping
Serotype analysis was performed using an agglutination
assay with monoclonal antibodies against type 2 fimbriae
(Fim2; NIBSC, 04 ⁄ 154) and type 3 fimbriae (Fim3, NIBSC,
04 ⁄ 156) according to EU pertstrain group recommenda-
tions (http://www.eupertstrain.org). Briefly, 15 ll of bacte-
rial suspension in PBS was mixed on slide with an equal
volume of 1 ⁄ 10 dilution of monoclonal antibodies against
Fim2 and 1 ⁄ 100 dilution of monoclonal antibodies against
Fim3. If the agglutination reaction was obtained with
either Fim2, Fim3, or both antibodies, the serotype was
defined as Fim2, Fim3 or Fim2,3, respectively. If no reac-
tion was detected, the serotype was defined as untypeable.
Autoagglutination was examined with phosphate-buffered
saline in parallel with monoclonal antibodies.
Membrane protein enrichment for two-dimensional
polyacrylamide gel electrophoresis (2-DE)
Membrane fractions were prepared as described previ-
ously (Bottero et al. 2007). Briefly, Bord. pertussis cells
were harvested by centrifugation (10 000 g; 30 min; 4°C)
and washed twice with low-salt washing buffer containing
3 mmol l)1 KCl, 68 mmol l)1 NaCl, 1Æ5 mmol l)1
KH2PO4 and 9 mmol l
)1 NaH2PO4. The cells were sus-
pended in 10 mmol l)1 Tris–HCl (pH 8Æ5) supplemented
with phenylmethylsulphonyl fluoride and protease inhibi-
tor cocktail tablets (Roche Applied Science, Buenos Aires,
Argentina) and then disrupted with an ultrasonicator
(Sonics & Materials, Inc., Danbury, CT, USA). DNase
and RNase (20 lg ml)1 each) were added to the cell sus-
pension, and the mixture was incubated at 37°C for 1 h.
The unbroken cells were removed by centrifugation
(12 000 g; 30 min; 4°C), and the supernatant was
retained. Total membrane proteins were then collected by
centrifugation (30 000 g, 1 h; 4°C) and resuspended in
7 mol l)1 urea, 2 mol l)1 thiourea, 10% isopropanol and
2% Triton X-100. Membrane proteins were divided into
aliquots and stored at )20°C.
Sample preparation, 2-DE and protein identification
were repeated at least four times for each strain.
Protein quantification
Protein concentrations were determined by the Bradford’s
method (Bradford 1976) with bovine serum albumin
(Sigma) as a standard.
2-DE
The method previously described by Bottero et al. (2007)
was followed. Seven-centimetre Immobiline DryStrip
(IPG, pH 4–7; Amersham Biosciences) dissolving 200 lg
of the membrane proteins in a volume of 125 ll of rehy-
dration buffer (7 mol l)1 urea, 2 mol l)1 thiourea, 10%
isopropanol and 2% Triton X-100) plus 1Æ25 ll 28% dith-
iothreitol (DTT), 0Æ62 ll 0Æ5% ampholyte (pH 4Æ0–7Æ0
[Amersham]) and 0Æ01% bromophenol blue was rehydrat-
ed overnight at room temperature. Three preset pro-
grammes were executed with slight modifications so that
the focusing conditions consisted of the conditioning
step, voltage ramping and final focusing. After IEF, the
strips were equilibrated in 50 mmol l)1 Tris buffer (pH
8Æ8) containing 6 mol l)1 urea, 2% sodium dodecyl sul-
phate, 30% glycerol and 1% DTT, followed by another 1-
h equilibration step with the same buffer supplemented
with 4Æ5% iodoacetamide. SDS-PAGE was performed
according to (Laemmli 1970) with a 12Æ5% resolving
polyacrylamide gel without a stacking gel. Separation in
the second dimension was carried out at 40 V at 4°C
until the running dye reached the bottom of the gel.
Proteins were visualized using a colloidal Coomassie
staining method (http://prospector.ucsf.edu) with the
modifications described previously (Bottero et al. 2007).
A gel image was captured in a UVP Bioimaging system
Epi Chemi3 Darkroom with a Hamamatsu Photonic
systems camera, model 1394 C8484-51-03G, controlled
by Labworks image acquisition and analysis software ver-
sion 4.6.00.0. The 8-bit grey-scale tif files obtained were
later processed with the Image Master 2D Platinum
software ver. 6.0 (GE Heathcare Argentina S.A., CABA,
Argentina).
MALDI-TOF-MS analysis and database search
Coomassie-stained spots were excised from 2-DE gels
for tryptic in-gel digestion and MALDI-TOF-MS with
an Ultraflex (Bruker) (Bottero et al. 2007). Peptide
mass fingerprint (PMF) data were searched against the
NCBI database in MASCOT server (http://www.matrix-
science.com) for sequence match. The MASCOT search
parameters were as follows: (i) species, bacteria (eubac-
teria); (ii) allowed number of missed cleavages (only
for trypsin digestion), 1; (iii) variable post-transla-
tional modification, methionine oxidation; (iv) fixed
modification, carbamidomethylation; (v) peptide toler-
ance, ±50 ppm; (vi) peptide charge, +; and (vii) mono-
isotopic peptide masses that were used to search the
database, allowing a molecular mass range for 2-DE
analyses of ±15%. Only significant hits as defined by
MASCOT probability analysis were considered. Predic-
tion of protein localization was carried out using a
PSORTb.2, PSORTb.3 algorithm available at http://
psort.nibb.ac.jp.and Proteome Analyst (PA) (Lu et al.
2004).
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Results
Genotypic analysis
Chromosomal DNA samples from Bp137 and two other
vaccine strains (Bp10536 and Bp509) used in some Latin
America countries were digested with XbaI and examined
by PFGE. The profiles obtained were compared with that
from the reference strain Tohama I (Fig. 1a). The profiles
were distributed in three groups classified according to a
criterion of similarity higher than 80%. The vaccine strain
Bp137 grouped with Bp509 in PFGE group III. The simi-
larity between these strains was 83%. Group I included
Bp10536, and group II was composed of the Japanese
vaccine strain Tohama I.
The representative isolate Bp106 collected after the
introduction of a massive vaccination programme in
Argentina is clearly separated from vaccine strains as we
previously reported (Bottero et al. 2007).
Regarding the genotypification of well-known polymor-
phic sequences described for virulence factors of
Bord. pertussis, vaccine strains Bp137 and Bp509 present
pertussis toxin promoter ptxP2 and the allele fim2-2.
These genotypes are different from those of the other
vaccine strains (Fig. 1b).
In contrast, the representative clinical isolate Bp106
contained ptxP3, ptxA1, prn2, fim2-1 and fim3-B alleles.
In fact, we observed this genotype in the majority of the
current members of our collection of circulating clinical
isolates (data not shown). Regarding the fim2 and fim3
alleles, 97% of the collection, including the Bp106 repre-
sentative strain, is fim2-1 and 76% has the variant B for
the fim3 allele. In relation to the fim3 allele, the vaccine
strains included in our study have the variant A.
The Fim serotypes are Fim2 for Tohama I strain and
Fim2,3 for Bp10536, Bp137 and Bp509. In our study, the
Fim serotype for Bp106 and for 97% of clinical isolates of
our collection was Fim3.
Proteomic analysis
We characterized Bp137 strain by proteomic analysis and
compared its surface proteome with the proteomes of the
other strains previously reported but repeated here
(Bottero et al. 2007; Supporting Information, Fig. S1). In
the analysis, we also included the data of human and
murine immunoproteomes already performed (Altindis
et al. 2009; Zhu et al. 2010; Tefon et al. 2011).
The 2-DE profile of Bp137 revealed more than 90 pro-
tein spots from which 50 proteins were successfully iden-
tified (Fig. 2). For this work, we have repeated the 2-DE
of surface proteins of the other four strains (Bp10536,
Bp509, Tohama I and Bp106). In all instances, we have
confirmed previously published data, but in addition, we
have identified more spots (64 spots in total). Of the total
identified peptide subunits, 12 were predicted to be asso-
ciated with the external membrane ⁄ extracellular localiza-
tion, ten had periplasmic localization, nine had
cytoplasmic membrane localization, eight had an
unknown or undefined origin and 25 had a cytoplasmic
localization (Table 3). As observed for the other vaccine
strains, some of the proteins separated by 2-DE were
present as multiple spots exhibiting variability in pI val-
ues (horizontal spot patterns, Fig. 2). Charge variants
included the following proteins: EF-Tu, 60-kDa chapero-
nin, outer membrane porin protein precursor, serum
resistance protein and serine protease. These may repre-
sent natural isoforms or an artefact caused by sample
preparation or 2-DE.
From the proteins identified by MALDI–TOF-MS, 14
are involved in small-molecule metabolism (BP2360,
BP0277, BP2439, BP2386, BP3288, BP3125, BP0995,
BP0379, BP3215, BP1126, BP0844, BP1499, BP0843 and
BP0047), seven are associated with macromolecule bio-
synthesis and degradation (BP2434, BP0007, BP3642,
BP2361, BP1420, BP1455 and BP2470), 15 are classified
in the category cell structure (BP1146, BP1296, BP3405,
Dice (Opt:1·50%) (Tol 1·5%–1·5%) (H>0·0% S>0·0%) [0·0%–100·0%]
PFGE-XbaI
10
0
908070
Bp10536
BpTohamaI
Bp137
Bp509
Bp106
Strain/Isolate Allelic variant of Fimbrial Serotype
ptxP ptxA prn fim2 fim3
TohamaI 1 2 1 1 A 2
Bp509 2 4 7 2 A 2, 3
Bp10536 1 2 1 1 A 2, 3
Bp137 2 4 1 2 A 2, 3
3 1 2 1 B 3Bp106
(a) (b)
Figure 1 (a) Genomic analysis of Bordetella pertussis strains used for vaccine production. The chromosomal DNA profiles obtained after digestion
with XbaI are shown on the left side and the identifier of strains on the right side. (b) Characteristics of vaccine strains used in this work.
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BP0840, BP1440, BP3862, BP0943, BP2513, BP2755,
BP3150, BP1630, BP2750, BP3559, BP3077 and BP1485),
14 are associated with cellular processes (BP3757, BP1487,
BP3322, BP0965, BP3495, BP1285, BP2761, BP3794,
BP2747, BP3552, BP1774, BP2235, BP2499 and BP2744),
two have general regulatory roles (BP2483 and BP2435),
three are associated with phages, transposons and patho-
genicity islands (BP2667, BP3494 and BP1054) and,
finally, six have unknown function (BP3441, BP2196,
BP3128, BP3515, BP2964 and BP1203) according to Riley
categories (Riley 1993).
Twenty of the 64 identified proteins were not detected
in at least one of the strains studied, and four proteins
were detected only in the local isolate Bp106 (Table 3).
Tohama I and Bp509 have very similar protein profiles
with only one differential subunit peptide (spot 10). How-
ever, these two strains share the expression of only three
of the 24 differential proteins with Bp137. Interestingly,
we note that seven of 24 peptide subunits were expressed
exclusively by the vaccine strain Bp137 and the clinical iso-
late Bp106. Peptide subunit Bp2235 (spot53), a potential
protein of type III secretion system (TTSS), belongs to this
group of seven subunits. Two other proteins identified
only in Bp106 and Bp137, but not detected in the rest of
the vaccine strains, are BP3150 and BP1630, assigned to
polysaccharide biosynthesis and capsule biosynthesis (spot
41 and spot 42, respectively, in Bp137).
Human immunoproteomic data recently published
(Zhu et al. 2010) include 16 of the 64 polypeptides here
identified, indicating that they are immunogenic
(Table 3). Other ten were detected to be reactive against
murine immune serum. Five of them were reactive
against both sera. Three of the five are present in all the
strains here included and correspond to well-known anti-
gens of Bord. pertussis: 60-kDa chaperonin (spot 14),
pertactin (spot 19) and serum resistance protein (spot 32)
(Altindis et al. 2009; Zhu et al. 2010; Tefon et al. 2011)
(Table 3). Other proteins such as BP1285, BP3642 and
BP0844 are among the differential proteins here detected.
Discussion
Here, we showed that the PFGE of the Bord. pertussis
strain Bp137 and two other strains included in wP vac-
cines in Latin America were distributed in three groups
classified according to a criterion of similarity higher than
80%. Although this observation of the vaccine strain
PFGE profiles is similar to that previously reported in
other countries (Caro et al. 2005), it is still important for
our region. The current PFGE classifies strains that were
not studied before and that are currently included in the
national immunization schedules of Latin American
countries (e.g. the Brazilian vaccine strain Bp137 and
strain Bp10536, which is included in vaccines used in
Argentina). The representative isolate Bp106, collected
after the introduction of generalized vaccination in
Argentina, is clearly separated from vaccine strains as we
previously reported (Bottero et al. 2007).
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Figure 2 2-D proteome of Bordetella pertussis vaccine strain Bp137. Preparations of membrane-enriched protein samples were separated by IEF
at pH 4–7 in the first dimension and then by 12Æ5% SDS-PAGE in the second dimension. Protein spots were visualized by colloidal Coomassie
staining. The spot numbers refer to the identified peptide subunits by MALDI-TOF.
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As expected, the above-mentioned Bord. pertussis wP
vaccine strains contain the characteristic ptxA, prn and
fim3 gene alleles of the old Bord. pertussis strains (Fig. 1b)
(Cassiday et al. 2000; Gzyl et al. 2001; Hardwick et al.
2002a; Fiett et al. 2003). The vaccine strains Bp137 and
Bp509, however, present different characteristics from
those of the other vaccine strains: pertussis toxin
promoter ptxP2 and the allele fim2-2 instead ptxP1 and
fim2-1. The ptxP2 allele was found in the Netherlands at
a frequency of 43% and in the United States at 29% dur-
ing the prevaccination period. In the Netherlands, this
allele was also detected during the 1999–2000 period, but
at a very low frequency (0Æ003%). Bart et al. (2010)
showed that strains that harbour this ptxP2 allele repre-
sented a distinct lineage that diverged from other strains
relatively early in the evolutive history of Bord. pertussis.
The ptxP2 and also ptxP1 strains are nearly completely
replaced in the late 1990s by the ptxP3 strains. In the
Netherlands, the increase in the frequency of ptxP3 strains
was associated with the resurgence of pertussis. The ptxP3
strains produced more Ptx than the ptxP1 strain, and epi-
demiological data suggest that ptxP3 strains are more vir-
ulent. The ptxP3 strains have spread worldwide, being the
predominant allele in our country (Mooi et al. 2009; Bart
et al. 2010).
Regarding circulating bacteria, we observed that Bp106,
as well as the majority of the current members of our
collection, contains ptxP3, ptxA1, prn2, fim2-1 and
fim3-B alleles (data not shown). The replacement of
ptxP1, ptxA2 or ptxA4, prn1 or prn7 strains by ptxP3,
ptxA1 and prn2 strains in recent times is a global phe-
nomenon that has been observed in other countries (van
Gent et al. 2009; Kallonen and He 2009; Mooi 2010;
Advani et al. 2011).
Regarding the fim2 allele, 97% of the collection, includ-
ing the Bp106 representative strain, is fim2-1. This finding
agrees with observations made in the UK, where fim2-1
has been the prevalent allele since 1920, and in the Neth-
erlands, where it has been the prevalent allele since 1965
(Van Loo and Mooi 2002; Packard et al. 2004). In rela-
tion to the fim3 allele, vaccine strains included in our
study have the variant A, which was found in 24% of the
isolates of our collection. The representative local strain,
Bp106, has the allele B, similar to 76% of the circulating
bacteria. This finding agrees with results from Finland
prior to 1999, Canada prior to 1990 and Russia prior to
1969, as all isolates in those countries at those times con-
tained the variant A. Isolates obtained from those coun-
tries after those years contained the predominant allele B
(Tsang et al. 2004; Kallonen and He 2009).
The Fim serotypes are Fim2 for Tohama I strain and
Fim2,3 for Bp10536, Bp137 and Bp509. In our study, the
Fim serotype for Bp106 and for 97% of clinical isolates
was Fim3. The serotype for these circulating bacteria cor-
related with observations in other populations where
Fim3 is the most frequent (Tsang et al. 2004; Heikkinen
et al. 2008; Kallonen and He 2009; Kurova et al. 2010;
Zhang et al. 2010; Advani et al. 2011).
Regarding the proteomic analysis here performed, the
2-DE profile of Bp137 revealed more than 90 protein
spots from which 50 proteins were successfully identified
(Fig. 2). Sixteen polypeptides from the total identified
seem to be immunogenic in humans as it was recently
published (Zhu et al. 2010).
Comparative analysis of the proteomes showed that
Bp137 and Bp106 present seven proteins that are not
detected in the other strains. One of these seven proteins
is BP2235, which is a potential protein of TTSS (spot 52).
This result is striking because previously we found that
the TTSS is expressed in bacteria that have recently been
in contact with the host, whereas in laboratory-adapted
vaccine strains, this expression would not occur (Gaillard
et al. 2011). In contrast to those findings, here we
observed the expression of TTSS components in the vac-
cine strain Bp137, even when this strain is adapted to
growth in laboratory conditions. This result suggests that
the expression of TTSS in this strain is governed by a dif-
ferent regulatory mechanism than in other vaccine strains.
Whatever the molecular mechanism, whose identification
is not within the scope of this work, the expression of
TTSS components in Bp137 is a desirable feature in a
vaccine strain, not only because the TTSS is immunogenic
but also because it shares a property with circulating clin-
ical isolates (Fennelly et al. 2008; Medhekar et al. 2008;
Zongfu Wu et al. 2008).
Two other proteins identified only in Bp106 and Bp137
but not detected in the rest of the vaccine strains are
BP3150, which is assigned to polysaccharide biosynthesis,
and BP1630, which is assigned to capsule biosynthesis
(spot 41 and spot 42, respectively, in Bp137). Bacterial
capsules allow pathogens to evade host defences. The
expression of capsule proteins in these strains, therefore,
could indicate the need to overcome the host immune
response induced by vaccination.
Our results show that, among the vaccine strains stud-
ied here, the strain Bp137 is the one that shares the high-
est number of proteins detected in the surface proteome
with the representative circulating bacteria Bp106. Inter-
estingly, some of these common proteins have immuno-
genic properties. Based on these results and taking into
account the previous reports showing that phenotypic
and genotypic divergence between strains could have an
impact in protection (King et al. 2001; Bottero et al.
2007), we suggest that vaccines containing Bp137 could
be appropriate to improve the control of pertussis in our
region.
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